Modern Slavery Act 2025

Modern Slavery Statement

This statement is made pursuant to section 54(1) of the Modern Slavery Act 2015 (the Act) and sets out the steps taken by Acacium Group Limited and the following entities in preventing modern slavery and human trafficking in its business and supply chains: Independent Clinical Services Limited, Pulse Healthcare Limited, Proclinical Limited, Liquid Personnel Limited and ICS Operations Limited.

In this statement the terms Acacium Group or the Group mean Acacium Group Limited and its subsidiaries, as defined in the Companies Act 2006.

This statement covers the calendar year 2025, which is also Acacium Group’s financial year.

Organisational Structure, Business and Supply Chains

Acacium Group is the leading global healthcare delivery partner offering: staffing, managed services and innovative delivery models to health and social care systems and the global life sciences industry. It comprises market leading specialist brands, which combine workforce, services, deep clinical expertise, technology and analytics to deliver better outcomes for clients and patients.  

At the Group’s core is its purpose to ‘improve people’s lives through expert healthcare, social care and life sciences’.  This drives everything we do and extends to a commitment to act ethically and with integrity in all our business dealings and relationships.  We report annually on our commitment to being a responsible business in our Responsible Business Report. (2025 report will be published in July 2026).

The nature of our business is that it is ‘people-driven’ and ‘tech-enabled’ with most Group spend being allocated to maintaining and building our workforce and the various technology systems and products we use to run our businesses and serve our customers. Whilst we do deliver certain healthcare services, which are regulated by the appropriate regulators in the UK, we do not operate any healthcare facilities. Our supply chain mainly consists of third-party recruitment and talent acquisition agencies, who may be engaged to support us to deliver to our clients, and other goods and services needed to operate our business such as IT and stationery.

Due Diligence Processes

Our principal business relationships are with the healthcare professionals and life science specialists who we introduce to, or deploy into, our clients’ businesses. We have extensive systems and processes in place as part of our recruitment, screening, and onboarding procedures, which, in part, serve to reduce the risk of candidates, who are victims of modern slavery or human trafficking, from being engaged by one of our businesses.

We continue to use a supplier due diligence questionnaire and code of conduct, in our most international division (Life Sciences), to gather detailed information from suppliers including on modern slavery incidents, policies, procedures and compliance. Such information is used to inform any further questioning and analysis by us of that supplier on modern slavery risk in their business or supply chain. This due diligence tool will be rolled out to the wider Group in due course as part of the sustainable procurement policy.

Risk assessment and management

Whilst our supply base is limited, and most of our business is carried out in countries that have a low prevalence of modern slavery (being Western Europe, the United States and Australia), we recognise that modern slavery is a complex global issue particularly relevant to (amongst others) the healthcare sector.

In 2025, we strengthened our Responsible Business approach by relaunching a single Group-wide Responsible Business network to support employee awareness and engagement on issues including modern slavery.

In terms of managing risks within our businesses, the controls in place as part of the recruitment, onboarding and deployment of workers are key. We also always seek to ensure appropriately robust modern slavery compliance obligations are included in our supplier contracts (managed through our contract lifecycle management system ‘IronClad’).

On the operational side, we believe that the Group’s safeguarding policies and requirements for front-line healthcare workers to have the appropriate level of safeguarding training are key to address front-line risk when workers are caring for vulnerable adults or young people. The support and tools available for colleagues and workers to raise concerns internally (including through the Group’s incident reporting system ‘InPhase’, which now includes Modern Slavery as a sub-category of Safeguarding, and via an independent confidential helpline for colleagues) further helps to manage the risk of any such abuse going undetected or unreported.

Measuring effectiveness

We have continued to maintain a qualitative approach and not yet adopted any rigid performance indicators, which seek to determine how effective the Group is at ensuring slavery or human trafficking is not taking place in any of our businesses or supply chain.

Policies

The Group Clinical Director and Group Director of People and Culture are responsible for the policy management, control and administration of the policy development process which includes maintaining a central register of all policies, ensuring policies are reviewed in a timely manner, ensuring consistency through the policy development process, archiving superseded policies onto Acacium Group Pages and removing superseded policies.

Several Group policies specifically address the risk of modern slavery at a front-line level. They are the ‘Safeguarding and Protecting Adults at Risk Policy’ and the ‘Safeguarding and Protecting Children Policy’ (both reviewed biennially). These policies include detail on warning signs and how to escalate/report concerns. In 2025 the Group launched an Anti-Harassment, Bullying and Domestic Abuse Policy, strengthening protections for colleagues, and supporting a culture where concerns can be raised and addressed. More broadly the Group has Whistleblowing Policies covering employees, workers and external partners. These are designed to encourage the raising of genuine concerns of wrongdoing or harm across our businesses. Other relevant policies include our Clinical Governance Policy, Recruitment and Selection Policy, Equality, Diversity and Inclusion Rights Policy and Complaints Policy.

In 2025 the Group also launched a new Code of Business Conduct for all colleagues setting out clear expectations for ethical behaviour and speaking up.

Training

Training is essential to ensure our colleagues and workers understand this issue properly, and how to respond, in the context of their working environment. All Acacium Group employees complete an annual Legal and Ethical Business training course (which includes a module on Modern Slavery). All our UK workers, who are healthcare practitioners, follow the Royal College of Nursing’s Intercollegiate Document on Safeguarding which require all such workers to have completed either Level 2 or Level 3 Safeguarding training as a pre-requisite to deployment.

This statement was approved by the Board of Directors of Acacium Group Limited on 24 June 2026.

Mike Barnard

Chief Executive Officer
24 June 2026

View 2024 statement View 2023 statement